Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THOR-707 (pegenzileukin) in advanced or metastatic solid tumors
NCT04009681Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Jun 2019
- Primary completion
- Dec 2025
- Modality
- Cytokines & Interferons
- Countries
- 6
01
Overview
Phase 2, open-label trial of pegenzileukin in metastatic solid tumors (8 cohorts), sponsored by Sanofi. Primary endpoints: Rate of Dose-Limiting Toxicities, Maximum Tolerated Dose and 3 more. Started Jun 2019; status: terminated.
02
Drugs
pegenzileukin
03
Conditions
metastatic solid tumors
Beyond the preview
Go deeper on NCT04009681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04009681.